( Toronto:RVX )

News from Resverlogix Corp. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Sep 13, 2017, 18:41 ET Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis

CALGARY, Sept. 13, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed its unaudited...


Sep 05, 2017, 07:00 ET Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement

CALGARY, Sept. 5, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed the...


Aug 30, 2017, 05:40 ET El éxito en el ensayo de inflamación CANTOS apoya la base del ensayo en marcha BETonMACE de Resverlogix

Resverlogix Corp. ("Resverlogix" o "la compañía") (TSX:RVX) se complace al anunciar los principales descubrimientos del ensayo CANTOS...


Aug 29, 2017, 12:56 ET Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial

CALGARY, Aug. 29, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that key findings from...


Aug 28, 2017, 07:00 ET Resverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction

CALGARY, Aug. 28, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the following update on its...


Jul 25, 2017, 18:30 ET Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017

CALGARY, July 25, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it filed its audited...


Jul 25, 2017, 09:00 ET Resverlogix recibe aprobación de la FDA para incluir pacientes en el ensayo en Fase 3 BETonMACE

- Resverlogix recibe la ruta de aprobación de la FDA para la inclusión de pacientes de Estados Unidos en el ensayo en Fase 3 BETonMACE...


Jul 25, 2017, 09:00 ET Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial

"BETonMACE Phase 3 Trial with apabetalone to expand to include the United States" CALGARY, July 25, 2017 /PRNewswire/ - Resverlogix Corp....


Jul 10, 2017, 07:00 ET Resverlogix selecciona el primer paciente para el ensayo clínico de fase 3 BETonMACE

- Resverlogix selecciona aleatoriamente el primer paciente en Taiwán y China para el ensayo clínico de fase 3 BETonMACE Resverlogix Corp....


Jul 10, 2017, 07:00 ET Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial

CALGARY, July 10, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that the first patient has been...


Jun 28, 2017, 07:00 ET Resverlogix Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone

A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without...


Jun 05, 2017, 06:55 ET Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017

CALGARY, June 5, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that a recently submitted...


May 31, 2017, 08:39 ET Resverlogix celebra un simposio centrado en epigenética en el ERA-EDTA Congress de Madrid, España

El simposio titulado "Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?" del ERA-EDTA Congress destaca la inhibición BET y...


May 31, 2017, 07:00 ET Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain

The symposium titled: "Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?" at the ERA-EDTA Congress highlights BET-inhibition and...


May 30, 2017, 07:00 ET Resverlogix recibe la aprobación de Health Canada para proceder con el ensayo clínico en enfermedad de Fabry

Apabetalone se expande para ser el primer ensayo clínico de enfermedad huérfana en pacientes con enfermedad de Fabry Resverlogix Corp....


May 30, 2017, 07:00 ET Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone

Apabetalone expands in to first orphan disease clinical trial in patients with Fabry disease CALGARY, May 30, 2017 /PRNewswire/ - Resverlogix...


May 23, 2017, 11:36 ET Reciente publicación y solicitud de patente de apabetalone apoya su desarrollo continuado y éxito

Nature Reviews Nephrology y Pfizer Inc. tratan la inhibición bromodominio BET y apabetalone como candidatos a fármacos viables Resverlogix...


May 23, 2017, 07:00 ET Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success

Nature Reviews Nephrology and Pfizer Inc. discuss BET bromodomain inhibition and apabetalone as viable drug candidates CALGARY, May 23, 2017...


May 15, 2017, 12:09 ET Resverlogix recibe aprobación de la FDA para un ensayo clínico de Apabetalone

- Resverlogix recibe la aprobación de la División Cardiovascular y Renal de la FDA para proceder a un ensayo clínico solicitado de Apabetalone...


May 15, 2017, 09:35 ET Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial

Apabetalone expands to a second major clinical indication in kidney dialysis patients CALGARY, May 15, 2017 /PRNewswire/ - Resverlogix Corp....


Mar 17, 2017, 07:00 ET Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities

A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without...


Mar 15, 2017, 07:00 ET Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office

CALGARY, March 15, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced the receipt of a Notice of...


Feb 23, 2017, 07:00 ET Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial

Protocol comments and recommendations incorporated CALGARY, Feb. 23, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:...


Feb 13, 2017, 07:00 ET Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease

Emergence of new potential indications for apabetalone (RVX-208) via third party research CALGARY, Feb. 13, 2017 /PRNewswire/ - Resverlogix Corp....


Jan 23, 2017, 07:00 ET Resverlogix proporciona resultados revolucionarios en pacientes con discapacidad renal severa

Varias proteínas clave que impulsan la enfermedad del riñón (renal) y el riesgo de diálisis están poco reguladas tras una sola dosis de...